nach oben

Metabolic Brain Disease

Erschienen in:

13.02.2019 | Original Article

Evidence for an association of serum melatonin concentrations with recognition and circadian preferences in patients with schizophrenia

verfasst von: Cigdem Sahbaz, Omer Faruk Özer, Ayse Kurtulmus, Ismet Kırpınar, Fikrettin Sahin, Sinan Guloksuz

Erschienen in: Metabolic Brain Disease | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Abstract

Melatonin, a neuro-differentiation factor, may play a role in the neurodevelopmental origins of schizophrenia. Cognitive impairment and decreased melatonin are reported in schizophrenia; however, the relationship between them remains unclear. We hypothesised that patients with schizophrenia would have lower concentrations of circulating melatonin than healthy controls and that melatonin levels would be associated with cognitive impairment. This study included 47 patients with schizophrenia and 40 healthy controls (HC). Serum melatonin concentrations were measured using the enzyme-linked immunosorbent assay. Positive and Negative Syndrome Scales (PANSS), The Morningness-Eveningness Questionnaire (MEQ), Pittsburgh Sleep Quality Index (PSQI), the Stroop and Oktem verbal memory processes (VMPT) tests were applied. Patients with schizophrenia had lower levels of melatonin compared to the HC group (p = 0.016), also after controlling for age, sex, and body mass index (BMI) (p = 0.024). In patients with schizophrenia, melatonin concentrations were associated with higher BMI (rho = 0.34, p = 0.01) and lower MEQ score (rho = −0.29, p = 0.035). The patient sample was split into low and high melatonin categories by using the median melatonin concentration in HC as the cut-off. Patients in the low melatonin group had poorer performance in VMPT-Recognition (p = 0.026) and Stroop-Colour Error (p = 0.032). Notwithstanding its limitations, the findings of this exploratory study suggest that decreased serum melatonin concentrations observed in schizophrenia might also be associated with cognitive impairment and circadian preferences. Future studies are required to investigate the role of melatonergic pathways in patients with schizophrenia.

Afonso P, Brissos S, Figueira ML, Paiva T (2010) Discrepant nocturnal melatonin levels in monozygotic twins discordant for schizophrenia and its impact on sleep. Schizophr Res 120:227–228. https://doi.org/10.1016/j.schres.2010.03.031 CrossRefPubMed

Afonso P, Figueira ML, Paiva T (2011) Sleep-promoting action of the endogenous melatonin in schizophrenia compared to healthy controls. Int J Psychiatry Clin Pract 15:311–315. https://doi.org/10.3109/13651501.2011.605954 CrossRefPubMed

Aleman A, Hijman R, de Haan EH, Kahn RS (1999) Memory impairment in schizophrenia: a meta-analysis. Am J Psychiatry 156:1358–1366 https://doi.org/10.1176/ajp.156.9.1358

Anderson G, Maes M (2012) Melatonin: an overlooked factor in schizophrenia and in the inhibition of anti-psychotic side effects. Metab Brain Dis 27:113–119. https://doi.org/10.1007/s11011-012-9307-9 CrossRefPubMed

Balikci K, Aydin O, Tas C, Esen Danaci A (2018) Oxytocin and social cognition in patients with schizophrenia: comparison with healthy siblings and healthy controls. Psychiatry and Clinical Psychopharmacology 28:123–130. https://doi.org/10.1080/24750573.2017.1387405 CrossRef

Beckmann H, Wetterberg L, Gattaz WF (1984) Melatonin immunoreactivity in cerebrospinal fluid of schizophrenic patients and healthy controls. Psychiatry Res 11:107–110CrossRefPubMed

Benloucif S, Burgess HJ, Klerman EB, Lewy AJ, Middleton B, Murphy PJ, Parry BL, Revell VL (2008) Measuring melatonin in humans. J Clinical Sleep Med: JCSM : Official Publication American Academy Sleep Med 4:66–69

Bersani G, Garavini A, Iannitelli A, Quartini A, Nordio M, Di Biasi C, Pancheri P (2002) Reduced pineal volume in male patients with schizophrenia: no relationship to clinical features of the illness. Neurosci Lett 329:246–248CrossRefPubMed

Bersani G, Mameli M, Garavini A, Pancheri P, Nordio M (2003) Reduction of night/day difference in melatonin blood levels as a possible disease-related index in schizophrenia. Neuro Endocrinol Lett 24:181–184PubMed

Bromundt V, Koster M, Georgiev-Kill A, Opwis K, Wirz-Justice A, Stoppe G, Cajochen C (2011) Sleep-wake cycles and cognitive functioning in schizophrenia. Br J Psychiatry 198:269–276. https://doi.org/10.1192/bjp.bp.110.078022 CrossRefPubMed

Bruno A, Zoccali RA, Abenavoli E, Pandolfo G, Scimeca G, Spina E, Muscatello MR (2014) Augmentation of clozapine with agomelatine in partial-responder schizophrenia: a 16-week, open-label, uncontrolled pilot study. J Clin Psychopharmacol 34:491–494. https://doi.org/10.1097/jcp.0000000000000157 CrossRefPubMed

Buysse DJ, Reynolds CF, 3rd, Monk TH, Berman SR, Kupfer DJ (1989) The Pittsburgh sleep quality index: a new instrument for psychiatric practice and research. Psychiatry Res 28:193–213

Cercos MG, Galvan-Arrieta T, Valdes-Tovar M, Solis-Chagoyan H, Argueta J, Benitez-King G, Trueta C (2017) Abnormally increased secretion in olfactory neuronal precursors from a case of schizophrenia is modulated by melatonin: a pilot study. Int J Mol Sci 18. https://doi.org/10.3390/ijms18071439

De Berardis D et al (2015) Agomelatine beyond borders: current evidences of its efficacy in disorders other than major depression. Int J Mol Sci 16:1111–1130. https://doi.org/10.3390/ijms16011111 CrossRefPubMedPubMedCentral

Fanget F, Claustrat B, Dalery J, Brun J, Terra JL, Marie-Cardine M, Guyotat J (1989) Nocturnal plasma melatonin levels in schizophrenic patients. Biol Psychiatry 25:499–501CrossRefPubMed

Findikli E, Inci MF, Gokce M, Findikli HA, Altun H, Karaaslan MF (2015) Pineal gland volume in schizophrenia and mood disorders. Psychiatr Danub 27:153–158PubMed

Galvan-Arrieta T et al (2017) The role of melatonin in the neurodevelopmental etiology of schizophrenia: a study in human olfactory neuronal precursors. J Pineal Res 63. https://doi.org/10.1111/jpi.12421

Gupta M (2010) Depression in systemic lupus erythematosus: a systematic review. Indian J Psychiatry 52:21–27. https://doi.org/10.4103/2321-6662.210493 CrossRefPubMedPubMedCentral

Horne JA, Ostberg O (1976) A self-assessment questionnaire to determine morningness-eveningness in human circadian rhythms. Int J Chronobiol 4:97–110PubMed

Jiang HK, Wang JY (1998) Diurnal melatonin and cortisol secretion profiles in medicated schizophrenic patients. J Formos Med Assoc 97:830–837PubMed

Kamath A, Rather ZA (2018) Melatonin for atypical antipsychotic-induced metabolic adverse effects: a meta-analysis of randomized controlled trials. Biomed Res Int 2018:8–8. https://doi.org/10.1155/2018/4907264 CrossRef

Kanne SM, Balota DA, Spieler DH, Faust ME (1998) Explorations of Cohen, Dunbar, and McClelland's (1990) connectionist model of Stroop performance. Psychol Rev 105:174–187CrossRefPubMed

Krystal AD, Thakur M, Roth T (2008) Sleep disturbance in psychiatric disorders: effects on function and quality of life in mood disorders, alcoholism, and schizophrenia. Ann Clin Psychiatry 20:39–46. https://doi.org/10.1080/10401230701844661 CrossRefPubMed

Larson J, Jessen RE, Uz T, Arslan AD, Kurtuncu M, Imbesi M, Manev H (2006) Impaired hippocampal long-term potentiation in melatonin MT2 receptor-deficient mice. Neurosci Lett 393:23–26. https://doi.org/10.1016/j.neulet.2005.09.040 CrossRefPubMed

Liebrich LS, Schredl M, Findeisen P, Groden C, Bumb JM, Nolte IS (2014) Morphology and function: MR pineal volume and melatonin level in human saliva are correlated. J Magn Reson Imaging 40:966–971. https://doi.org/10.1002/jmri.24449 CrossRefPubMed

Mann K et al (2006) Nocturnal hormone profiles in patients with schizophrenia treated with olanzapine. Psychoneuroendocrinology 31:256–264. https://doi.org/10.1016/j.psyneuen.2005.08.005 CrossRefPubMed

Manoach DS, Pan JQ, Purcell SM, Stickgold R (2016) Reduced sleep spindles in schizophrenia: a treatable Endophenotype that links risk genes to impaired cognition? Biol Psychiatry 80:599–608. https://doi.org/10.1016/j.biopsych.2015.10.003 CrossRefPubMed

Miller CL, Llenos IC, Dulay JR, Weis S (2006) Upregulation of the initiating step of the kynurenine pathway in postmortem anterior cingulate cortex from individuals with schizophrenia and bipolar disorder. Brain Res 1073-1074:25–37. https://doi.org/10.1016/j.brainres.2005.12.056 CrossRefPubMed

Modabbernia A, Heidari P, Soleimani R, Sobhani A, Roshan ZA, Taslimi S, Ashrafi M, Modabbernia MJ (2014) Melatonin for prevention of metabolic side-effects of olanzapine in patients with first-episode schizophrenia: randomized double-blind placebo-controlled study. J Psychiatr Res 53:133–140. https://doi.org/10.1016/j.jpsychires.2014.02.013 CrossRefPubMed

Monteleone P, Maj M, Fusco M, Kemali D, Reiter RJ (1992) Depressed nocturnal plasma melatonin levels in drug-free paranoid schizophrenics. Schizophr Res 7:77–84CrossRefPubMed

Monteleone P, Natale M, La Rocca A, Maj M (1997) Decreased nocturnal secretion of melatonin in drug-free schizophrenics: no change after subchronic treatment with antipsychotics. Neuropsychobiology 36:159–163. https://doi.org/10.1159/000119377 CrossRefPubMed

Monti JM, BaHammam AS, Pandi-Perumal SR, Bromundt V, Spence DW, Cardinali DP, Brown GM (2013) Sleep and circadian rhythm dysregulation in schizophrenia. Prog Neuro-Psychopharmacol Biol Psychiatry 43:209–216. https://doi.org/10.1016/j.pnpbp.2012.12.021 CrossRef

Morera-Fumero AL, Abreu-Gonzalez P (2013) Role of melatonin in schizophrenia. Int J Mol Sci 14:9037–9050. https://doi.org/10.3390/ijms14059037 CrossRefPubMedPubMedCentral

Morera-Fumero AL, Abreu-Gonzalez P, Henry-Benitez M, Diaz-Mesa E, Yelmo-Cruz S, Gracia-Marco R (2013) Chronotype as modulator of morning serum melatonin levels. Actas Esp Psiquiatr 41:149–153PubMed

Naismith SL, Hermens DF, Ip TK, Bolitho S, Scott E, Rogers NL, Hickie IB (2012) Circadian profiles in young people during the early stages of affective disorder. Transl Psychiatry 2:e123. https://doi.org/10.1038/tp.2012.47 CrossRefPubMedPubMedCentral

Oktem O (1992) A verbal test of memory processes: a preliminary study. Archives of Neuropsychiatry 29:196–206

Palmese LB, DeGeorge PC, Ratliff JC, Srihari VH, Wexler BE, Krystal AD, Tek C (2011) Insomnia is frequent in schizophrenia and associated with night eating and obesity. Schizophr Res 133:238–243. https://doi.org/10.1016/j.schres.2011.07.030 CrossRefPubMedPubMedCentral

Pocivavsek A, Rowland LM (2018) Basic neuroscience illuminates causal relationship between sleep and memory: translating to schizophrenia. Schizophr Bull 44:7–14. https://doi.org/10.1093/schbul/sbx151 CrossRefPubMed

Punduk Z, Gur, H, Ercan I (2005) A reliability study of the Turkish version of the mornings-evenings questionnaire Turk Psikiyatri Derg 16:40–45

Ragland JD, Ranganath C, Harms MP, Barch DM, Gold JM, Layher E, Lesh TA, MacDonald AW III, Niendam TA, Phillips J, Silverstein SM, Yonelinas AP, Carter CS (2015) Functional and neuroanatomic specificity of episodic memory dysfunction in schizophrenia: a functional magnetic resonance imaging study of the relational and item-specific encoding task. JAMA Psychiatry 72:909–916. https://doi.org/10.1001/jamapsychiatry.2015.0276 CrossRefPubMedPubMedCentral

Rao ML, Gross G, Strebel B, Braunig P, Huber G, Klosterkotter J (1990) Serum amino acids, central monoamines, and hormones in drug-naive, drug-free, and neuroleptic-treated schizophrenic patients and healthy subjects. Psychiatry Res 34:243–257CrossRefPubMed

Rao ML, Gross G, Strebel B, Halaris A, Huber G, Braunig P, Marler M (1994) Circadian rhythm of tryptophan, serotonin, melatonin, and pituitary hormones in schizophrenia. Biol Psychiatry 35:151–163CrossRefPubMed

Rawashdeh O, de Borsetti NH, Roman G, Cahill GM (2007) Melatonin suppresses nighttime memory formation in zebrafish. Science 318:1144–1146. https://doi.org/10.1126/science.1148564 CrossRefPubMed

Rimmele U, Spillmann M, Bartschi C, Wolf OT, Weber CS, Ehlert U, Wirtz PH (2009) Melatonin improves memory acquisition under stress independent of stress hormone release. Psychopharmacology 202:663–672. https://doi.org/10.1007/s00213-008-1344-z CrossRefPubMed

Robillard R, Rogers NL, Whitwell BG, Lambert T (2012) Are cardiometabolic and endocrine abnormalities linked to sleep difficulties in schizophrenia? A hypothesis driven review Clin Psychopharmacol Neurosci 10:1–12. https://doi.org/10.9758/cpn.2012.10.1.1 CrossRefPubMed

Robinson S, Rosca P, Durst R, Shai U, Ghinea C, Schmidt U, Nir I (1991) Serum melatonin levels in schizophrenic and schizoaffective hospitalized patients. Acta Psychiatr Scand 84:221–224CrossRefPubMed

Ryan MC, Flanagan S, Kinsella U, Keeling F, Thakore JH (2004) The effects of atypical antipsychotics on visceral fat distribution in first episode, drug-naive patients with schizophrenia. Life Sci 74:1999–2008. https://doi.org/10.1016/j.lfs.2003.08.044 CrossRefPubMed

Sandyk R, Kay SR (1991) Pineal calcification in schizophrenia. Relationship to age of onset and tardive dyskinesia. Schizophr Res 5:85–86CrossRefPubMed

Smith JA, Mee TJ, Barnes JL (1977) Elevated melatonin serum concentrations in psychiatric patients treated with chlorpromazine. J Pharm Pharmacol 29:30P–30PCrossRefPubMed

Smith JA, Mee TJ, Padwick DJ, Spokes EG (1981) Human post-mortem pineal enzyme activity. Clin Endocrinol 14:75–81CrossRef

Suresh Kumar PN, Andrade C, Bhakta SG, Singh NM (2007) Melatonin in schizophrenic outpatients with insomnia: a double-blind, placebo-controlled study. J Clin Psychiatry 68:237–241CrossRefPubMed

Tek C, Palmese LB, Krystal AD, Srihari VH, DeGeorge PC, Reutenauer EL, Guloksuz S (2014) The impact of eszopiclone on sleep and cognition in patients with schizophrenia and insomnia: a double-blind, randomized, placebo-controlled trial. Schizophr Res 160:180–185. https://doi.org/10.1016/j.schres.2014.10.002 CrossRefPubMedPubMedCentral

Thakore JH, Mann JN, Vlahos I, Martin A, Reznek R (2002) Increased visceral fat distribution in drug-naive and drug-free patients with schizophrenia. Int J Obes Relat Metab Disord 26:137–141. https://doi.org/10.1038/sj.ijo.0801840 CrossRefPubMed

Tripathi A, Kar SK, Shukla R (2018) Cognitive deficits in schizophrenia: understanding the biological correlates and remediation strategies. Clin Psychopharmacol Neurosci 16:7–17. https://doi.org/10.9758/cpn.2018.16.1.7 CrossRefPubMedPubMedCentral

Wang Z, Liu D, Zhan J, Xie K, Wang X, Xian X, Gu J, Chen W, Hao A (2013) Melatonin improves short and long-term neurobehavioral deficits and attenuates hippocampal impairments after hypoxia in neonatal mice. Pharmacol Res 76:84–97. https://doi.org/10.1016/j.phrs.2013.07.008 CrossRefPubMed

Wirz-Justice A, Cajochen C, Nussbaum P (1997) A schizophrenic patient with an arrhythmic circadian rest-activity cycle. Psychiatry Res 73:83–90CrossRefPubMed

Wulff K, Joyce E, Middleton B, Dijk DJ, Foster RG (2006) The suitability of actigraphy, diary data, and urinary melatonin profiles for quantitative assessment of sleep disturbances in schizophrenia: a case report. Chronobiol Int 23:485–495. https://doi.org/10.1080/07420520500545987 CrossRefPubMed

Wulff K, Dijk DJ, Middleton B, Foster RG, Joyce EM (2012) Sleep and circadian rhythm disruption in schizophrenia. Br J Psychiatry 200:308–316. https://doi.org/10.1192/bjp.bp.111.096321 CrossRefPubMedPubMedCentral

Titel: Evidence for an association of serum melatonin concentrations with recognition and circadian preferences in patients with schizophrenia
verfasst von: Cigdem Sahbaz
Omer Faruk Özer
Ayse Kurtulmus
Ismet Kırpınar
Fikrettin Sahin
Sinan Guloksuz
Publikationsdatum: 13.02.2019
Verlag: Springer US
Erschienen in: Metabolic Brain Disease / Ausgabe 3/2019
Print ISSN: 0885-7490
Elektronische ISSN: 1573-7365
DOI: https://doi.org/10.1007/s11011-019-00395-3

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2019

Selective inhibition of intestinal 5-HT improves neurobehavioral abnormalities caused by high-fat diet mice

Genistein induces degradation of mutant huntingtin in fibroblasts from Huntington’s disease patients

Neuroprotective effect of ethanol and Modafinil on focal cerebral ischemia in rats

Association of PTTG1 polymorphism rs1895320, rs2910200 and rs6882742 with non-functioning pituitary adenomas in Chinese Han population: a case-control study

Protocatechuic acid attenuate depressive-like behavior in olfactory bulbectomized rat model: behavioral and neurobiochemical investigations